Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Biophytis S.A. BPTS
$2.78
+$0.29 (10.32%)
На 18:04, 12 мая 2023
Ключевые показатели
-
Marketcap
10177998.00000000
-
week52high
15.60
-
week52low
3.24
-
Revenue
0
-
P/E TTM
0
-
Beta
1.16641200
-
EPS
-18.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
18 апр 2023 г. в 04:00
Описание компании
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 25 окт 2021 г. | |
| HC Wainwright & Co. | Buy | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022
Benzinga
07 апр 2022 г. в 08:15
Biophytis SA (NASDAQ: BPTS) said that it is currently assessing FDA comments and recommendations and preparing to submit Phase 2-3 trial designs for sarconeos (BIO101) trial in sarcopenia. Enrollment is expected to start in 2H of 2022 in the SARA Phase 2 trial.
Why Are Biophytis Shares Trading Higher During Premarket Trading?
Benzinga
03 февр 2022 г. в 09:03
Biophytis SA BPTS has received approval from the ANVISA (Brazilian health authority) for its Expanded Access Program (EAP) to treat hospitalized patients with severe COVID-19 with Sarconeos (BIO101). Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.